Search
Confirm
Close

ABOUT Viwit

With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life

COMPANY PROFILE

    Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.

    Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has three integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.

PRODUCT INTRODUCTION

We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation


HIGH DEMAND PRODUCTS

Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services

Title

Levofloxacin Hydrochloride Injection 5ml: 0.5g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.5g<br/>
Title

Levofloxacin hydrochloride Injection 5ml: 0.3g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.3g<br/>
Title

Puerarin Injection 5ml: 0.25g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.25g<br/>
Title

Puerarin Injection 8ml: 0.4g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;8ml: 0.4g<br/>

INNOVATION 

& collaboration platform 

CDMO

Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). 

威智医药

Project Collaboration

Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.              

威智医药
威智医药

Joint Venture

Provide marketing, fund raising and other resources.

In-/Out-Licensing

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

威智医药

NEWS CENTER

Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.

2024

09 -23

From July 15 to 19, 2024, FDA inspectors conducted a five-day on-site cGMP (Current Good Manufacturing Practice) inspection of Viwit Pharmaceuticals Co., Ltd. (referred to as Viwit API manufacturing facility). Recently, the FDA's official website showed that Viwit's API manufacturing facility successfully passed the cGMP on-site audit with a perfect result of NAI, meaning "Zero 483". This is the second time Viwit's API manufacturing facility has successfully passed the U.S. FDA audit, further affirming Viwit’s robust and continuous production management and quality systems.

2024

09 -18

Viwit Pharmaceuticals (Viwit), an innovation driven biopharmaceutical and healthcare company has entered into an exclusive licensing and supply agreement with Zydus Lifesciences Ltd.’s wholly owned subsidiary, Zydus Lifesciences Global FZE for Gadobutrol Injection (generic version of GADAVIST) and Gadoterate Meglumine Injection (generic version of DOTAREM) for the US market.

2024

08 -14

Recently, Viwit Pharmaceutical’s self-developed Lifitegrast API has completed the registrations in China and the United States. The API registration number is Y20240000726, and the US DMF number is 040172.

2024

07 -15

Recently, theViwit independently developed smoking cessation drug Varenicline (Tartrate) Tablets, in strengths of 0.5 mg and 1 mg, received the Drug Registration Certificate issued by the South African Health Products Regulatory Authority (SAHPRA).

2024

07 -12

On July 5, 2024, Viwit Pharmaceitical’s independently developed Fosaprepitant Dimeglumine API received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA). The registration number is Y20220000736, and the notice number is 2024YS00664.